IMRXImmuneering Corp
Earnings
When Immuneering Corp reports, what it reported each quarter, and how the stock took the results.
27 quarters. Mar 31, 2020 to Sep 30, 2026. USD.
Next results · Q4 2026Projected
Mar 5, before the open
Fri, Mar 5, 2027in 108 days
Projected from its last 8 releases. The company has not named the day yet.
- Quarter
- Q4 2026 · Ends about Dec 31, 2026
- 10-K window
- Mar 1 – 23
Read against Q4 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- —
- Revenue, change from a year earlier: Q4 2023 −100.0%, Q3 2023 −100.0%, Q2 2023 −100.0%, Q1 2023 −100.0%
- Net income
- -$11.58M
- Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
- EPS
- —
- EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m
Latest results
- Revenue
- —
- —
- Net income
- -$24.19M
- N/M
- EPS
- -$0.37
- N/M
- Revenue
- —
- —
- Net income
- -$17.27M
- N/M
- EPS
- -$0.27
- N/M
- Revenue
- —
- —
- Net income
- -$13.46M
- N/M
- EPS
- -$0.21
- N/M
- Revenue
- —
- —
- Net income
- -$11.58M
- N/M
- EPS
- —
- —
All quarters
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Move | Source trail |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2026 | ||||||||||
| Q3 2026 | Sep 30, 2026 | Oct 29, 2026 · after-hours | Oct 29, 2026 | 29 d | 10-Q | — | — | -$0.37 | 7.0% | |
| Q2 2026 | Jun 30, 2026 | Aug 5, 2026 · pre-market | Aug 5, 2026 | 36 d | 10-Q | — | — | -$0.27 | 0.5% | |
| Q1 2026 | Mar 31, 2026 | May 15, 2026 · pre-market | May 15, 2026 | 45 d | 10-Q | — | — | -$0.21 | +0.4% | |
| FY 2025 | ||||||||||
| Q4 2025derived | Dec 31, 2025 | Mar 6, 2026 · pre-market | Mar 6, 2026 | 65 d | 10-K | — | — | — | +6.8% | |
| Q3 2025 | Sep 30, 2025 | Nov 12, 2025 · after-hours | Nov 12, 2025 | 43 d | 10-Q | — | — | -$0.38 | 2.6% | |
| Q2 2025 | Jun 30, 2025 | Aug 13, 2025 · after-hours | Aug 13, 2025 | 44 d | 10-Q | — | — | -$0.40 | 6.3% | |
| Q1 2025 | Mar 31, 2025 | May 5, 2025 · after-hours | May 5, 2025 | 35 d | 10-Q | — | — | -$0.42 | 2.4% | |
| FY 2024 | ||||||||||
| Q4 2024derived | Dec 31, 2024 | Mar 20, 2025 · after-hours | Mar 20, 2025 | 79 d | 10-K | — | — | — | +9.8% | |
| Q3 2024 | Sep 30, 2024 | Nov 13, 2024 · after-hours | Nov 13, 2024 | 44 d | 10-Q | — | — | -$0.49 | +13.5% | |
| Q2 2024 | Jun 30, 2024 | Aug 6, 2024 · after-hours | Aug 6, 2024 | 37 d | 10-Q | — | — | -$0.47 | 8.1% | |
| Q1 2024 | Mar 31, 2024 | May 7, 2024 · after-hours | May 7, 2024 | 37 d | 10-Q | — | — | -$0.49 | 5.5% | |
| FY 2023 | ||||||||||
| Q4 2023derived | Dec 31, 2023 | Mar 1, 2024 · pre-market | Mar 1, 2024 | 61 d | 10-K | $0.00 | −100.0% | — | — | |
| Q3 2023 | Sep 30, 2023 | Nov 9, 2023 · after-hours | Nov 9, 2023 | 40 d | 10-Q | $0.00 | −100.0% | -$0.43 | 12.0% | |
| Q2 2023 | Jun 30, 2023 | Aug 3, 2023 · after-hours | Aug 3, 2023 | 34 d | 10-Q | $0.00 | −100.0% | -$0.43 | 2.2% | |
| Q1 2023 | Mar 31, 2023 | Apr 18, 2023 · pre-market | May 4, 2023 | 34 d | 10-Q | $0.00 | −100.0% | -$0.51 | — | |
| FY 2022 | ||||||||||
| Q4 2022derived | Dec 31, 2022 | Mar 6, 2023 · after-hours | Mar 6, 2023 | 65 d | 10-K | $455.00 | −99.8% | — | +6.2% | |
| Q3 2022 | Sep 30, 2022 | Nov 10, 2022 · pre-market | Nov 10, 2022 | 41 d | 10-Q | $38.38K | −92.0% | -$0.49 | — | |
| Q2 2022 | Jun 30, 2022 | Aug 10, 2022 · after-hours | Aug 10, 2022 | 41 d | 10-Q | $94.42K | −85.7% | -$0.44 | — | |
| Q1 2022 | Mar 31, 2022 | May 10, 2022 · pre-market | May 10, 2022 | 40 d | 10-Q | $183.70K | −75.4% | -$0.49 | +3.0% | |
| FY 2021 | ||||||||||
| Q4 2021derived | Dec 31, 2021 | Mar 10, 2022 · pre-market | Mar 10, 2022 | 69 d | 10-K | $189.59K | — | — | 7.3% | |
| Q3 2021 | Sep 30, 2021 | Nov 9, 2021 · pre-market | Nov 9, 2021 | 40 d | 10-Q | $482.13K | −29.4% | -$0.47 | 10.2% | |
| Q2 2021 | Jun 30, 2021 | Sep 9, 2021 · pre-market | Sep 9, 2021 | 71 d | 10-Q | $660.04K | +37.3% | -$1.61 | — | |
| Q1 2021 | Mar 31, 2021 | — | — | — | — | $748.20K | — | -$1.26 | — | |
| FY 2020 | ||||||||||
| Q4 2020derived | Dec 31, 2020 | — | — | — | — | — | — | — | — | |
| Q3 2020 | Sep 30, 2020 | — | — | — | — | $682.57K | — | -$0.89 | — | |
| Q2 2020 | Jun 30, 2020 | — | — | — | — | $480.84K | — | -$0.73 | — | |
| Q1 2020 | Mar 31, 2020 | — | — | — | — | — | — | — | — | |
Earlier years, FY 2020 to FY 2023The latest three years
Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Source filings
Provenance
ProvenanceData status and checks
Immuneering Corp · CIK 1790340 · Engraved from SEC EDGAR